Showing results (211-220 of 264) with videos related to

Sort By:
Pageof 27
Cancer Medicine|December 2, 2016
Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective studyJihyun Kwon, Chang-Ki Min, Kihyun Kim, et al.
Anticancer Research|September 15, 2019
A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESOPRESSO)Sook Ryun Park, Dok Hyun Yoon, Jong Hoon Kim, et al.
American Journal of Hematology|January 11, 2020
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)Ho Sup Lee, Kihyun Kim, Seok Jin Kim, et al.
Journal of Hematology & Oncology|February 16, 2021
Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 studyHuiqiang Huang, Jun Zhu, Ming Yao, et al.
Cancer Research and Treatment|December 30, 2014
Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter AnalysisJunshik Hong, Seok Jin Kim, Jae-Sook Ahn, et al.
Scientific Reports|January 1, 2020
Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysisJung Yong Hong, Dok Hyun Yoon, Sang Eun Yoon, et al.
Annals of Hematology|September 8, 2019
Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphomaJun Ho Yi, Gyeong-Won Lee, Young Rok Do, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2024
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II StudyLihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
Blood|June 12, 2026
Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01)Won Seog Kim, Seok Jin Kim, Dok Hyun Yoon, et al.
Cancer Research and Treatment|July 16, 2024
Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC StudyYoon Seok Choi, Joonho Shim, Ka-Won Kang, et al.
Pageof 27